Table 1. Therapeutic Hair Regrowth Outcomes of Contact Immunotherapy in Patients With Alopecia Areataa.
| Sensitizer and AA Subtype | Any Regrowth | Minor Regrowth | Major Regrowth | Complete Regrowth | ||||
|---|---|---|---|---|---|---|---|---|
| Response Rate, % (95% CI) | No. of Studies (No. of Patients) | Response Rate, % (95% CI) | No. of Studies (No. of Patients) | Response Rate, % (95% CI) | No. of Studies (No. of Patients) | Response Rate, % (95% CI) | No. of Studies (No. of Patients) | |
| Diphenylcyclopropenone | ||||||||
| PA | 75.5 (67.6-82.0) | 8 (248) | 63.7 (55.1-71.6) | 15 (315) | 55.4 (41.4-68.7) | 12 (322) | 41.6 (27.9-56.8) | 13 (311) |
| AT/AU | 51.6 (42.0-61.1) | 9 (193) | 45.0 (35.1-55.2) | 14 (279) | 28.3 (22.4-35.0) | 12 (326) | 22.0 (15.2-30.6) | 13 (366) |
| Overall | 63.8 (55.0-71.7) | 9 (441) | 54.5 (47.2-61.6) | 16 (594) | 38.9 (29.2-49.6) | 13 (648) | 30.7 (22.9-39.6) | 13 (677) |
| Squaric acid dibutyl ester | ||||||||
| PA | 74.2 (60.8-84.3) | 7 (211) | 66.5 (50.2-79.6) | 6 (106) | 51.8 (37.4-65.8) | 6 (120) | 50.5 (17.2-83.4) | 4 (60) |
| AT/AU | 61.5 (45.5-75.4) | 7 (92) | 45.0 (22.4-69.9) | 6 (78) | 25.0 (16.5-36.0) | 6 (79) | 35.0 (18.6-55.9) | 5 (77) |
| Overall | 67.8 (57.8-76.5) | 7 (303) | 57.9 (43.2-71.3) | 7 (184) | 38.4 (27.5-50.6) | 7 (199) | 38.4 (23.1-56.5) | 5 (137) |
| Overall | ||||||||
| PA | 74.6 (67.9-80.3) | 15 (459) | 64.9 (57.7-71.6) | 20 (409) | 56.1 (45.9-65.8) | 18 (430) | 42.6 (29.9-56.3) | 17 (371) |
| AT/AU | 54.5 (46.2-62.6) | 16 (285) | 45.0 (35.9-54.4) | 20 (357) | 28.7 (24.1-33.8) | 18 (405) | 24.9 (18.2-33.0) | 18 (443) |
| Overall | 65.5 (59.1-71.3) | 16 (744) | 55.5 (49.0-61.9) | 22 (766) | 39.4 (31.8-47.6) | 19 (835) | 32.3 (25.3-40.2) | 18 (814) |
Abbreviations: AA, alopecia areata; AT, alopecia totalis; AU, alopecia universalis; PA, patchy alopecia.
a
Any regrowth was less than 10% of hair loss; minor regrowth, 10% to 59%; major regrowth, 60% to 89%; and complete regrowth, 90% to 100%.